Table IV.
Correlation analysis of the methylation levels of 26 ovarian cancer drug resistance-related genes with DNA methylation and clinical factors of ovarian cancer.
| Gene | Methylation status of ovarian cancer | Invasion | Histological type | Grade | Stage | Relapse | Prognosis | Plasma | Refs. |
|---|---|---|---|---|---|---|---|---|---|
| hMLH1 | Hypermethylation (66) | Yes (66), LM (66) | Yes (66) | Yes (61) | – | Yes | Poor (PFS) (48) | Yes | (14) |
| BRCA1 | Hypermethylation | – | Yes (61) | Yes (61) | – | Yes (62) | Good (PFS) (64) | Yes (65,67) | (16) |
| FBXO32 | Hypermethylation | Yes | – | – | Yes | – | Poor (PFS) | – | (18) |
| MCJ | Hypermethylation | – | – | – | – | – | Poor (OS) (20) | – | (19,20) |
| TRAG-3 | Hypomethylation | – | – | – | – | – | Good (OS, PFS) (9) | – | (21) |
| CD133 | Hypermethylation | Yes | – | – | – | – | – | – | (22) |
| ASS1 | Hypermethylation | – | – | – | – | Yes | Poor (OS, RFS) | – | (23) |
| RASSF1A | Hypermethylation | Yes (66,68,69) | No (70) | Yes (70) | Yes (68,70,71) | – | Poor (PFS) (48) | Yes (65,67) | (24,25) |
| PTEN | Hypermethylation | Yes (72), LM (72) | Yes (61), No (73,74) | Yes (73) | Yes (73) | – | Poor (OS, PFS) (12) | – | (27) |
| DR4 | Hypermethylation | – | – | – | – | – | Poor (OS, PFS) (75) | Yes (76) | (29) |
| ABCG2 | Hypermethylation | – | – | – | – | – | – | – | (30) |
| BLU | Hypermethylation | – | – | – | – | – | Poor (OS, PFS) | – | (31,32) |
| MDR1 | Hypomethylation (11); Hypermethylation (10) | – | – | – | – | – | Poor (60) | – | – |
| TGFBI | Hypermethylation | – | No association (63) | No association (63) | No association (63) | – | No association (63) | – | (26,33,63) |
| RGS10 | Hypermethylation | – | – | – | – | – | No association | – | (34) |
| UCHL1 | Hypermethylation | – | Yes (77) | Yes (77) | Yes (77) | – | Yes (77) | – | (35,36) |
| HSulf-1 | Hypermethylation | – | – | – | – | – | – | – | (38) |
| SFRP | Hypermethylation | Yes | – | – | Yes (78,79) | Yes (39) | Poor (OS) (39) | – | (39) |
| MAL | Hypermethylation | – | – | – | Yes (80) | – | Poor (80) | – | (11) |
| TUBB3 | Hypomethylation | Yes, LM | – | – | Yes | – | Poor (OS and PFS) (81) | – | (41) |
| LINE-1 | Hypomethylation | Yes | Yes | Yes | Yes | – | Poor (OS and PFS) | Yes (67) | (42) |
| CLDN4 | Hypermethylation | Yes (44,45) | – | – | – | – | – | – | (43) |
| HOXA10 | Hypomethylation (47) | Yes (49) | Yes (82) | – | – | – | Poor (49) | – | – |
| HOXA9, HOXA11 | Hypermethylation | – | – | Yes | – | – | Poor (PFS) (81) | – | (50,51) |
| FANCF | Hypomethylation | – | – | – | Yes (83) | – | – | – | (52) |
-, no relevant studies; LM, lymphatic metastasis; OS, overall survival; PFS, progression-free survival.